Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126444751 | 12644475 | 1 | I | 20160808 | 20160811 | 20160811 | PER | PHEH2016US019939 | NOVARTIS | 0.00 | F | Y | 0.00000 | 20160811 | CN | COUNTRY NOT SPECIFIED | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126444751 | 12644475 | 1 | PS | EXTAVIA | INTERFERON BETA-1B | 1 | Subcutaneous | 0.062 MG (0.25 ML), QOD WEEKS 1-2 | U | 125290 | .062 | MG | |||||||
126444751 | 12644475 | 2 | SS | EXTAVIA | INTERFERON BETA-1B | 1 | Subcutaneous | 0.125 MG (0.5ML), QOD WEEKS 3-4 | U | 125290 | .125 | MG | |||||||
126444751 | 12644475 | 3 | SS | EXTAVIA | INTERFERON BETA-1B | 1 | Subcutaneous | 0.187MG (0.75ML), QOD WEEKS 5-6 | U | 125290 | .187 | MG | |||||||
126444751 | 12644475 | 4 | SS | EXTAVIA | INTERFERON BETA-1B | 1 | Subcutaneous | 0.25MG (1 ML), QOD WEEK 7+ | U | 125290 | .25 | MG |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
126444751 | 12644475 | 1 | Multiple sclerosis |
Outcome of event
no results found |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
126444751 | 12644475 | Injection site erythema | |
126444751 | 12644475 | Injection site pain | |
126444751 | 12644475 | Injection site reaction |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
no results found |